Abstract:
The present invention relates to a composition for inhibiting non-fluorescent advanced glycation end products, and a use thereof. More specifically, the present invention relates to: a composition for inhibiting non-fluorescent advanced glycation end products, comprising one or more strains selected from the group consisting of Lactobacillus sp. strains, Lactococcus sp. strains, Enterococcus sp. strains, Bifidobacterium sp. strains, Bacillus sp. strains, Saccharomyces sp. strains, Pediococcus sp. strains, and Leuconostoc sp. strains; and a food composition, a pharmaceutical composition, a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, which have an activity of reducing non-fluorescent advanced glycation end products and comprise the composition. In addition, the present invention relates to a method for producing a non-fluorescent advanced glycation end product inhibitor and a method for inhibiting non-fluorescent advanced glycation end products.
Abstract:
The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.
Abstract:
The present invention relates to a strain having liver function improving activity, and a use thereof. Specifically, the present invention relates to a health food composition for improving liver function and a pharmaceutical composition for improving liver function, which contain, as an active ingredient, one or more strains selected from the group consisting of a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, and a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a lysate thereof or a culture product thereof. The strain of the present invention shows excellent activity in inhibiting the activity of alanine aminotransferase (ALT) or aspartate aminotransferase (AST), inhibiting an increase in the concentration of total cholesterol or triglycerides in the liver, and inhibiting fat accumulation in the liver, thereby being effectively usable in the preparation of a food composition and a pharmaceutical composition for improving liver function.
Abstract:
The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for preventing and treating liver diseases. In addition, the present invention relates to a method for extracting narirutin from citrus peel, and a method for preparing citrus fermented milk using the same.
Abstract:
A product quality monitoring system includes: an RFID tag which is attached to a first packing container in which a product is packed, and transmits atmospheric history information and an identifier for a product distribution history; a QR code which is attached to a second packing container and stores the identifier and address information of a product quality predicting server; a product distribution history DB which stores the atmospheric history information and the identifier which are received from the RFID tag; a user terminal which connects with the product quality predicting server corresponding to the address information stored in the captured QR code, and requests a quality index of the product; and the product quality predicting server which calculates the quality index of the product or a time when the product has a specific quality index, from the atmospheric history information.
Abstract:
The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for preventing and treating liver diseases. In addition, the present invention relates to a method for extracting narirutin from citrus peel, and a method for preparing citrus fermented milk using the same.
Abstract:
A product quality monitoring system includes: an RFID tag which is attached to a first packing container in which a product is packed, and transmits atmospheric history information and an identifier for a product distribution history; a QR code which is attached to a second packing container and stores the identifier and address information of a product quality predicting server; a product distribution history DB which stores the atmospheric history information and the identifier which are received from the RFID tag; a user terminal which connects with the product quality predicting server corresponding to the address information stored in the captured QR code, and requests a quality index of the product; and the product quality predicting server which calculates the quality index of the product or a time when the product has a specific quality index, from the atmospheric history information.
Abstract:
The present invention relates to a novel strain having the activity of reducing advanced glycation end products and a use thereof and, more particularly, to a food composition having the activity of reducing advanced glycation end products and a pharmaceutical composition for preventing or treating a disease caused by advanced glycation end products each of which comprises a Lactococcus lactis KF140 (accession number KCCM11673P) strain, a Bacillus subtilis KF11 (accession number KCCM11981P) strain, a Lactobacillus pentosus KF8 (accession number KCCM11997P) strain, or a Lactobacillus paracasei KF00816 (accession number KCCM11998P) strain, which are all novel strains; a lysate thereof; or a culture thereof as an active ingredient. In addition, the present invention relates to a composition for intestinal regulation, a probiotic composition, a feed composition, and a fermented product, each of which comprises the novel strain of the present invention, a lysate thereof, or a culture thereof as an active ingredient.